| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead |
| Ongoing | 4 | 110 | Europe | Symtuza, Tablet, Symtuza, Triumeq | Fundación SEIMC-GESIDA, JANSSEN CILAG S.A | HIV VIH, HIV VIH, Diseases [C] - Virus Diseases [C02] | | | | |
DETOX, NCT03685500: A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c) |
|
|
| Completed | 4 | 78 | Europe | Symtuza® (TAF/FTC/DRV/c), ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c) | Fundacion SEIMC-GESIDA, Janssen-Cilag, S.A. | HIV Infections | 06/20 | 06/20 | | |
SymITA, NCT04240210: Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita) |
|
|
| Terminated | 4 | 1 | US | Symtuza | Midland Research Group, Inc., Janssen Pharmaceuticals | Human Immunodeficiency Virus | 12/21 | 12/21 | | |
NCT04442737: A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain |
|
|
| Completed | 4 | 103 | US | D/C/F/TAF FDC, TAF/FTC FDC, INI Based Regimen | Janssen Scientific Affairs, LLC | HIV-1 | 08/23 | 08/23 | | |
ReSTART, NCT04388904: Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. |
|
|
| Completed | 4 | 75 | US | Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC) | The Crofoot Research Center, Inc., Janssen Scientific Affairs, LLC | HIV-1-infection | 04/24 | 04/24 | | |
NCT05463783: Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain |
|
|
| Recruiting | 4 | 30 | US | Biktarvy, bictegravir/emtricitabine/tenofovir alafenamide, Symtuza, darunavir/cobicistat/emtricitabine/tenofovir alafenamide | East Carolina University, Janssen Scientific Affairs, LLC | HIV Infections, Obesity | 03/25 | 03/25 | | |
